Briacell Therapeutics
BCTX
20 hedge funds and large institutions have $452K invested in Briacell Therapeutics in 2024 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 2 closing their positions.
342% more call options, than puts
Call options by funds: $137K | Put options by funds: $31K
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
5% more funds holding
Funds holding: 19 → 20 (+1)
11.59% less ownership
Funds ownership: 13.73% → 2.14% (-12%)
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
93% less capital invested
Capital invested by funds: $6.38M → $452K (-$5.93M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$23.2K |
| 2 |
LPL Financial
San Diego,
California
|
+$21.8K |
| 3 |
Group One Trading
Chicago,
Illinois
|
+$20.7K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$5.94K |
| 5 |
Renaissance Technologies
New York
|
+$5.38K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KJHP
K.J. Harrison & Partners
Toronto,
Ontario, Canada
|
-$249K |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$147K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$97.9K |
| 4 |
Morgan Stanley
New York
|
-$39.6K |
| 5 |
RAM
Redmond Asset Management
Henrico,
Virginia
|
-$33.4K |
BCTX Hedge Fund Activity: Q2 2024 in Review
20 of the 6,936 institutional investors tracked by Wall St. Rank reported a position in Briacell Therapeutics (BCTX) for Q2 2024, worth a combined $452K — down 93% from $6.38M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new BCTX positions and 2 closed out — a net gain of 2 holders — while 4 added to existing stakes and 7 trimmed.
The largest buyer was XTX Topco, opening a new position worth an estimated $23.2K. The largest seller was K.J. Harrison & Partners, exiting entirely with an estimated $249K sold.
- 20 institutional investors held Briacell Therapeutics (BCTX) as of Q2 2024, up from 19 in Q1 2024.
- Funds reported $452K of Briacell Therapeutics stock for Q2 2024, down 93% quarter-over-quarter.
- 4 funds opened new Briacell Therapeutics positions in Q2 2024 and 2 closed out, a net change of +2 holders.
- The largest Briacell Therapeutics buyer in Q2 2024 was XTX Topco, an estimated $23.2K added.
- The largest Briacell Therapeutics seller in Q2 2024 was K.J. Harrison & Partners, an estimated $249K sold.
Based on aggregated 13F filings for Q2 2024.